Documenting hypoglycemia during clinical trials relies primarily on SMBG ≤ 70 mg/dL (3.9 mmol/L) with or without symptoms; however, hypoglycemia unawareness, sleep, and prandial-based sampling might lead to underestimation and lower detection of treatment differences. To quantify sensitivity and detection rates using CGM vs. SMBG, we analyzed hypoglycemia (Hypo: glucose ≤ 70 mg/dL) data from 73,941 SMBG samples collected simultaneously with masked CGM (iPro®2) during four 6-day CGM sessions (10,830 person-days) in 682 T2D patients participating in three 20-26 week trials testing insulin regimens [glargine with/without metformin, lispro, and peglispro (n = 539)] and triple oral combination therapy (n = 143). For SMBG vs. CGM, total Hypo events were 864 (n = 296 patients) vs. 2,935 (n = 494) at any time of day (daily), and 1(n = 61) vs. 1,209 (n = 383) nocturnally 12:01-6:00 AM. Poisson regression of Hypos and exposure time, with study regimen, time of day and monitoring method as independent variables, indicated CGM nocturnal Hypo risk [IRR (SE), 95% CI] was higher than CGM daily Hypo risk [1.665 (0.057), 1.558 to 1.781]. However, SMBG detected only 29.4% of CGM daily Hypos [0.294 (0.011), 0.273 to 0.318]. The interaction term indicated that the SMBG nocturnal detection bias resulted in 70% fewer Hypo events [0.303 (0.033), 0.246 to 0.375] than CGM, thereby detecting only 8.9% of those detected by CGM [0.089 (0.009), 0.073 to 0.109]. CGM also detected higher Hypo risk for insulin and metformin compared to triple oral combination therapy [daily = 1.16 (0.085), 1.007 to 1.340, p = 0.04; nocturnal = 1.247 (0.131), 1.015 to 1.531, p = 0.04] when A1C levels were comparable. SMBG did not detect these differences (p = 0.09 and p = 0.94). Using CGM vs. SMBG to detect hypoglycemia can improve comparative safety and risk-benefit assessments during diabetes clinical trials by providing greater sensitivity and representative 24-hour sampling.


M.A. Testa: Stock/Shareholder; Spouse/Partner; GI Windows, Inc.. Stock/Shareholder; Self; Phase V Technologies, Inc.. S. Saldivar-Salazar: None. M. Su: None. J.F. Hayes: None. D.C. Simonson: Advisory Panel; Self; GI Windows, Inc.. Stock/Shareholder; Self; GI Windows, Inc.. Stock/Shareholder; Spouse/Partner; Phase V Technologies, Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at